CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge by Guedán Carrió, Sònia & Alemany Bonastre, Ramon
MINI REVIEW
published: 23 October 2018
doi: 10.3389/fimmu.2018.02460







Ohio University, United States
Amorette Barber,








This article was submitted to
Cancer Immunity and Immunotherapy,
a section of the journal
Frontiers in Immunology
Received: 01 August 2018
Accepted: 04 October 2018
Published: 23 October 2018
Citation:
Guedan S and Alemany R (2018)
CAR-T Cells and Oncolytic Viruses:




CAR-T Cells and Oncolytic Viruses:
Joining Forces to Overcome the
Solid Tumor Challenge
Sonia Guedan 1* and Ramon Alemany 2
1Department of Hematology and Oncology, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer,
Barcelona, Spain, 2 ProCure Program, IDIBELL-Institut Catala d’Oncologia, L’Hospitalet de Llobregat, Spain
Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells has resulted
in unprecedented rates of long-lasting complete responses in patients with leukemia
and lymphoma. However, despite the impressive results in patients with hematologic
malignancies, CAR-T cells have showed limited effect against solid cancers. New
approaches will need to simultaneously overcome the multiple challenges that
CAR-T cells encounter in solid tumors, including the immunosuppressive tumor
microenvironment and heterogeneity of antigen expression. Oncolytic viruses are lytic
and immunogenic anti-cancer agents with the potential to synergize with CAR-T cells
for the treatment of solid tumors. In addition, viruses can be further modified to deliver
therapeutic transgenes selectively to the tumor microenvironment, which could enhance
the effector functions of tumor-specific T cells. This review summarizes the major
limitations of CAR-T cells in solid tumors and discusses the potential role for oncolytic
viruses as partners for CAR-T cells in the fight against cancer.
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INTRODUCTION
The recent approval by the US Food and Drug Administration (FDA) of two different CAR-T cell
therapies for the treatment of leukemia and lymphoma represents a landmark in the development
of cancer immunotherapies. Together with immune checkpoint blockade therapy (1), CAR-T cells
are revolutionizing the field of cancer therapy, providing hope for a cure in patients with previously
refractory cancers (2–8). However, despite the stunning results of CAR-T cells in patients with
hematologic malignancies, this approach has shown little effect in patients with solid tumors.
Recent clinical trials demonstrated that CAR-T cells are able to infiltrate the tumor mass and exert
antigen-directed activity (9–12). However, with rare exceptions (13, 14), observed responses in
patients with solid tumors have been minor and transient.
In order to induce complete responses in patients with solid tumors, CAR-T cells need
to overcome several barriers. First, CAR-T cells must traffic from the blood into the tumor,
infiltrate the tumor mass, and be able to survive and maintain their effector functions in a tumor
microenvironment that is highly immunosuppressed and enriched in stroma. Then, CAR-T cells
need to eliminate the totality of the cancer cells, which is extremely difficult due to the heterogeneity
of antigen expression in cancer cells and the intrinsic plasticity of tumors that may lead to tumor
escape (15, 16). Finally, CAR-T cells are living drugs that can lead to dramatic antitumor responses
but can also induce significant toxicities (17–19). New approaches to enhance therapeutic outcome
in patients with solid tumors must therefore focus on enhancing potency without increasing
toxicity.
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Rapid advances in synthetic biology, T cell immunology, and
gene editing have fueled the design of next generation CAR-
T cells with the potential to overcome some of the hurdles
encounter in solid tumors (20). However, it is unlikely that
CAR-T cell therapy alone will be sufficient to induce complete
responses in the majority of cancers. Combining CAR-T cells
with other cancer treatments that have different mechanisms of
action and the potential to synergize with T cells may reduce
tumor escape and increase the success rates of CAR-T cell
therapy. As novel therapies emerge, rational combinations will
need to be tested based on an understanding of the mechanisms
underlaying tumor resistance to CAR-T cells.
Oncolytic virotherapy is a therapeutic approach to treat
cancer that uses native or genetically modified viruses that
selectively replicate within cancer cells (21). The field of oncolytic
virotherapy has gained renewed attention after the FDA approval
of Talimogene laherparepvec (T-VEC), an oncolytic herpes
simplex virus type 1 (HSV-1) modified to express GM-CSF
(22), and the recent reports of high response rates obtained in
patients with advanced melanoma when combining T-VEC with
checkpoint blockade (23, 24). Oncolytic viruses (OV) mediate
their antitumor effect through a dual mechanism of action,
including a direct lytic effect on tumor cells and the induction
of anti-cancer adaptive immunity (25, 26). Moreover, OV can
be further modified to selectively deliver therapeutic transgenes
to the tumor microenvironment to enhance their antitumor
potency or boost an antitumor immune response (27). All these
characteristics make OV excellent potential partners to synergize
with emerging immunotherapies, and several combinatorial
approaches are being currently tested in preclinical and clinical
trials (26, 28).
This review provides an overview of current barriers that
CAR-T cells encounter in solid tumors, summarizes the advances
in the field of OV and discusses the preclinical and clinical
data that support the clinical testing of OV in combination with
CAR-T cells to overcome the solid tumor challenge.
CAR-T CELLS IN SOLID TUMORS:
CHALLENGES AND LIMITATIONS
While most of the early trials of CAR-T cells for solid tumors
resulted in poor therapeutic outcomes, some case reports of
dramatic clinical responses with manageable therapy-related
toxic effects provide clear reasons for optimism (13, 14). Recent
reports with second generation CAR-T cells suggest that CAR-
T cells can traffic, persist, and proliferate in the tumor (9,
10). Moreover, evidence of transient antitumor activity has
been observed in patients with difficult-to-treat tumors, such as
glioblastoma (13), neuroblastoma (14), pancreatic cancer (12),
and sarcoma. Here, we summarize the lessons learned in these
clinical trials and discuss the hurdles that CAR-T cells must
overcome for effective therapy, focusing on those challenges that
OV may help to address.
Trafficking, Proliferation, and Persistence
The ability of tumor-specific T cells to traffic to the tumor,
proliferate, and persist is considered critical to achieve an
effective anti-tumor response (14, 29, 30). While T cells can
actively traffic to sites of disease, often tumors present low
levels of inflammation and lack of the chemokines required for
migration. Also, physical barriers, such as aberrant vasculature,
increased stromal stiffness and high interstitial pressure, may
impair T-cell infiltration. Once in the tumor, CAR-T cells must
efficiently proliferate, and persist until the entirety of the tumor
is eliminated. However, T-cell proliferation and persistence
are often hampered due to T-cell intrinsic (T-cell fitness) or
extrinsic factors (tumor microenvironment). The requirements
for proliferation and persistence can be relaxed in some instances
if regional delivery and redosing of CAR-T cells is a therapeutic
option (31). For example, in a recent clinical trial, multiple
intracranial injections of CAR-T targeting IL13Rα2 mediated a
transient complete response in a patient with glioblastoma (13).
In this patient, two intracranial CAR-T cell delivery routes were
tested: intracavitary and intraventricular. While intracavitary
therapy was only able to control growth of the local tumor,
intraventricular therapy resulted in a dramatic reduction in the
size of all intracranial and spinal tumors. These results highlight
the importance of trafficking and administration route to achieve
the optimal tumor responses. Developing strategies to enhance
trafficking and persistence to increase the therapeutic CAR-T cell
input in the tumor would represent a vertical advance in the field.
Tumor Immunosuppression
On arrival to the tumor, CAR-T cells encounter an
immunosuppressive environment that prevents T-cells from
reaching their full therapeutic potential. The main barriers that
CAR-T cells need to overcome once in the tumor include: (i)
suppression by immunoregulatory cells, including myeloid-
derived suppressor cells (MDSC), tumor associated macrophages
and neutrophils, and regulatory T cells; (ii) presence of an array
of immunosuppressive molecules, such as IL-10, TGF-β, PD-L1,
IDO and arginase-1, and (iii) microenvironment factors, such
as hypoxia, low pH and nutritional depletion. These conditions,
together with chronic antigen exposure, can lead T-cells to
distinct stages of functional dysfunction (32–34). Moreover, the
stromal microenvironment can actively exclude T cells from
the vicinity of cancer cells (35). Finally, a recent clinical report
suggests that the tumor microenvironment can become even
more immunosuppressive after CAR-T cell activation within
the tumor, probably due to an initial production of IFN-γ
(10). Finding ways to prevent or reverse T-cell dysfunction by
reverting tumor immunosuppression will be key to improving
treatment.
Tumor Escape by Loss or Heterogeneity of
Antigen Expression
One of the main limitations in the treatment of solid tumors
with CAR-T cells is the absence of cancer-restricted antigens
that are uniformly expressed in tumor cells and absent in
essential organs. Solid tumors exhibit heterogeneity of antigen
expression with regards to intensity and distribution. Tumor
escape due to heterogeneity or loss of antigen expression is an
emerging threat to CAR-T cells, as it can result in overgrowth
of target-deficient tumor cells that are invisible to CAR-T cell
therapy (36–38). Preclinical studies have demonstrated that
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tumor cells expressing high levels of the targeted antigen are
preferentially eliminated by CAR-T cells, whereas those with the
lowest expression may survive (39–41). Decreased expression
of the targeted antigen after CAR-T cell therapy has been
observed in several clinical trials, including those targeting Her2
(9), EGFRviii (10), IL13Rα2 (11), and mesothelin (12). These
results demonstrate the potential of CAR-T cells to eliminate
antigen-positive tumor cells, but also highlight the importance
of designing new strategies to simultaneously target different
antigens. Several groups are designing new CAR constructs able
to target more than one antigen simultaneously (39, 42, 43).
While reducing the risk of escape, these strategies may also
result in increased on-target off-tumor reactivity, as most of the
targeted antigens can be expressed in healthy tissue at low levels
(17–19). An alternative approach would be to find strategies to
activate an endogenous immune response that could partner with
CAR-T cells to completely eliminate the tumor. Some reports
suggest that CAR-T-cell mediated tumor destruction may lead to
the release of other tumor antigens that are cross-presented in
a process known as epitope spreading (44, 45). This observation
requires further investigation, but it could explain how complete
elimination of tumor lesions has been achieved even when the
tumors did not uniformly express the target (13).
ONCOLYTIC VIRUSES: LESSONS
LEARNED IN CLINICAL TRIALS
To date, there are three viruses commercially available for
the treatment of cancer: T-VEC approved in the USA, H101
approved in China and Rigvir approved in Latvia, Georgia
and Armenia. Several other viruses are in clinical trials and
may eventually join this short list of marketed viruses (46).
Some of the lessons learned from clinical trials that will drive
the design of future therapies include: (a) OV can induce
a therapeutic benefit in cancer patients, including complete
responses, in the absence of severe adverse effects (47–50).
Interestingly, some of these complete responses are reached after
the virus have been eliminated, suggesting that the complete
elimination of the tumor may depend on the activation of
an immune-mediated anti-tumor response (48). On line with
this observation, a recent clinical trial reported that the overall
survival among patients who received a chimeric poliovirus
reached a plateau of 21% 1 year after treatment that was
sustained for months (51). This plateau in long-term survival
is similar to the one observed in Kaplan-Meier curves from
cancer patients treated with other cancer immunotherapies and
highlights the role of the immune system on the emergence of
long-term survivors (52); (b) The antiviral immunity constitutes
an obstacle against OV as it sequesters or neutralizes viral
particles before they reach their target. A major question is
how to deliver the virus to the tumor efficiently; (c) Virus
replication has been detected in tumor biopsies a few days after
treatment. However, the ability of OV to survive and spread
through the tumor is limited by antiviral T cells (47, 48, 53);
(d) Tumors treated with OV typically show increased immune
cell infiltration, including activated macrophages and cytotoxic
T-cells, and pro-inflammatory cytokines (47, 48, 53). Tumor-
specific T cells have been detected after treatment with OV
(53, 54). While the capacity of OV to expand neoantigen-specific
T cells deserves further investigation, the potential of OV for
combination with immunotherapies such as immune checkpoint
inhibitors has been well-recognized (28, 55–58). Several clinical
trials are currently testing the combination of OV with immune
checkpoint therapy and initial reports showed promising results
(23, 24).
ONCOLYTIC VIRUSES: THE IDEAL ALLIES
FOR CAR-T CELLS?
OV have the potential to synergize with CAR-T cells by helping
them simultaneously overcome some of the multiple barriers
found in solid tumors. First, viruses provide a danger signal
that can revert tumor immunosuppression, which could facilitate
CAR-T cell trafficking, proliferation, and persistence in the
tumor microenvironment. Second, the direct lytic effect of OV
on cancer cells results in tumor lysis and release of tumor-
associated antigens (TAA), which can induce an anti-tumor
adaptive response that could potentially mitigate tumor escape by
antigen loss. Third, OV can be armed with therapeutic transgenes
that could further enhance the effector functions of T cells.
Here, we provide an overview of the biological properties of
OV that may be considered when choosing a viral platform for
combination with CAR-T cells, and we summarize the recent
preclinical strategies that have been explored combining CAR-T
cells and OV.
Oncolytic Viruses as Immunotherapy
Agents
The immune system is well-equipped to mount an innate
inflammatory response to viruses that eventually will induce the
infiltration of effector T-cells. In particular, OV have pathogen-
associated molecular patterns (PAMPS) detected by pattern-
recognition receptors (PRRs) on tumor and epithelial cells as
well as macrophages and dendritic cells (59). These PRRs induce
danger associated molecular patterns (DAMPs) characteristic of
an immunogenic cell death (60, 61). PRRs also signal through
NF-kB to induce the expression of cytokines such as TNF-α
and IL6, and through IFN Regulatory Factor (IRF) to induce
type I interferons and activate caspase 1 that matures IL-1β
(62). This pro-immune cytokine environment can facilitate the
maturation and function of DC’s, macrophages, and epithelial
cells that can lead to the recruitment of neutrophils and natural
killer (NK) cells, monocytes, and memory T-cells to the site of
infection (63–65). Tumor cells dying due to the lytic activity of
OV can release TAA. Activated DC’s with their MHC loaded
with virus and/or tumor epitopes can traffic to the draining
lymph nodes to engage specific T-cells and stimulate their
proliferation and circulation into the bloodstream. Chemokines
of the infected tumors can induce integrin expression on these
T-cells and selectin expression on endothelial cells to extravasate
them. Under these conditions, T cells can be recruited efficiently
to infected tumors, and as discussed above, increased T cell
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infiltration is generally detected in tumors of patients treated
with OV therapy. Interestingly, viral infection has been shown
to induce neoantigen-directed T cell responses (53, 54), which
could synergize with CAR-T cells and virus-specific T cells to
clear the tumor. A mayor limitation to study the impact of the
immune-modulating effects of OV on CAR-T cell therapy is the
lack of good animal models. However, it can be hypothesized
that following the establishment of a more immunogenic
intratumoral milieu, killing of target cells may be more efficient
due to cooperation between the effector T-cells.
The ability of OV to induce an anti-tumor immune response
is now considered a key mechanism of action to obtain long-
term antitumor responses. Therefore, most of the current efforts
directed at enhancing the therapeutic potential of OV are focused
on improving their capacity to induce a systemic antitumor
response.
The Oncolytic Virus Armamentarium
Multiple types of viruses are used in cancer virotherapy, each
one of them with its unique properties (Table 1) (66). Here we
discuss some of the different factors that should be considered
when selecting an OV for combination with CAR-T cells. In
general terms, viruses that replicate in the cytoplasm (RNA
viruses) kill tumor cells faster than nuclear ones (DNA viruses)
as they do not need to reach the nucleus of the infected cells.
But for the same reason, they offer less opportunities for tumor-
selective control. Tumor-selective replication of most oncolytic
RNA viruses, such as reovirus, picornaviruses (Coxsackeivirus,
Rigavirus), rhabdovirus (Vesiscular Stomatitis Virus [VSV],
Maraba Virus), and paramixovirus (Measles Virus, Newcastle
disease virus [NDV]), depends on defects of the interferon
pathway in tumor cells. Because IFN induction is a central
pathway in the innate response to viruses, which potentiates
the adaptive T cell responses, the inflammatory response elicited
with these viruses is expected to be lower. DNA viruses, such as
adenoviruses, have slower replication cycles but are amenable to
being controlled in the nucleus of the infected cells using tumor-
selective promoters. The presence of an envelope also determines
the oncolytic properties of a virus. Enveloped viruses (i.e.,
Measles virus, NDV, VSV, Herpes simplex virus, and Vaccinia
virus) bud from cells and are less “lytic” than naked viruses.
The envelope also contributes to the main clearance mechanisms
in blood, with complement having a major role for enveloped
viruses and antibodies for non-enveloped ones. Size is also an
important parameter for the properties of OVs. The smaller the
virus, the easier it will be for the virus to penetrate and diffuse
throughout the tumor. But a larger virus with a larger genome
allows the insertion of non-viral transgenes. Arming OV with
therapeutic transgenes offer the opportunity to complement the
OV in multiple ways. Among RNA viruses, VSV, Measles virus,
and NDV can accept transgenes in contrast to picornaviruses and
reoviruses, and for DNA viruses, Adenovirus, Herpes Simplex
Virus andVaccinia virus can be armedwith transgenes in contrast
to parvovirus. The list of genes that have been included in OV
that could be potentially useful for combination with CAR-T
cells is long and it has been reviewed recently (67). It includes,
among others: (a) inducers of immunogenic cell death (68),
(b) transgenes directed to modulate the immune system, such
as cytokines (22, 69–71), chemokines (72, 73), co-stimulatory
proteins (74–77), bispecific T-cell engagers (BiTEs) (78, 79), and
immune checkpoint blockers (80–83), and (c) stroma-degrading
proteins that could facilitate the spread of OV and T-cells within
the tumors (84, 85). Comparing viruses and transgenes is a
very challenging task given the limitations of preclinical immune
competent mouse models, where many human viruses present
defects in replication and tumors do not edit the immune system
in a slow and progressive way as occurs in humans.
Combining CAR-T Cells and Oncolytic
Viruses for the Treatment of Solid Tumors
At a preclinical level, several groups have started to test
different transgene-armed OV in combination with CAR-T cells
(Figure 1). Most of these works assessed the antitumor effects
of these therapies in NOD scid gamma (NSG) mice, a mouse
strain that is completely deficient in adaptive immunity and
severely deficient in innate immunity (86). NSG mice allow the
engraftment and persistence of adoptively transferred CAR-T
cells, and human tumor xenografts allow the replication of the
virus and the delivery of the transgene. Therefore, these studies
gave important insights in the antitumor effects of combining
CAR-T cells with oncolysis and transgene delivery. An important
limitation is that the capacity of OV to induce anti-tumor
immunity cannot be assessed using these tumor xenografts.
Oncolytic adenoviruses modified to express IL-15 and
RANTES (87) or IL-2 and TNF-α (88) have been shown to
increase the accumulation and survival of CAR-T cells in the
tumor microenvironment. Similarly, with the goal of enhancing
the intra-tumoral trafficking of CAR-T cells, a vaccinia virus
expressing CXCL11, a CXCR3 ligand, was used to attract effector
cells following transfer (89). Another report demonstrated that
expression by an oncolytic adenovirus of a BiTE targeting a
second tumor antigen could address heterogeneity of antigen
expression (40). Combination of a preparation of CAR-T cells
with the OV-BiTE induced activation of T cells in the absence
of the CAR-targeted antigen or lack of CAR expression (i.e., non-
transduced T cell population). In a slightly different approach,
combination of an oncolytic adenovirus with a helper-dependent
adenovirus expressing a PD-L1 blocking mini-antibody was
used to revert T cell dysfunction by preventing PD1:PDL1
interaction (90). Co-expression of IL12p70 and PD-L1 further
augmented the therapeutic efficacy of the combination (91). As
expected, all these combinations of CAR-T cells and armed-OV
resulted in enhanced tumor control and prolonged survival when
compared to each agent as monotherapy. An interesting finding
by Watanabe et al. is that CAR-T cells as monotherapy failed
to control the growth of the primary tumor, while OV could
suppress the progression of the primary tumor but mice died
frommetastatic disease. Combination of CAR-T cells with an OV
armed with IL-2 and TNF-a was able to control both the primary
tumor and tumor metastasis (88).
Finally, in a totally different and very preliminary approach,
CAR-T cells have been used to deliver OV to the tumor (92).
Circulating cells such as lymphocytes, monocytes, erythrocytes,
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FIGURE 1 | Combination of CAR-T cells and oncolytic virus for the treatment of solid tumors. (A) CAR-T cells find several obstacles in solid tumors, including an
immunosuppressive environment that can lead to T cell dysfunction and treatment failure. (B) Cancer treatment with oncolytic viruses prior to CAR-T cell therapy
results in tumor debulking, immunogenic cell death and reverted tumor immunosuppression. (C) Oncolytic viruses can be genetically modified to deliver therapeutic
transgenes into the tumor microenvironment to enhance T-cell effector functions. Preclinical studies combining CAR-T cells with oncolytic viruses armed with
cytokines, chemokines, BiTEs, or immune checkpoint inhibitors resulted in enhanced therapeutic outcomes.
or even platelets can bind viruses and have shown tumor-
targeting properties (93–96). Loading OV onto tumor-specific T
cells (by adhesion to the T-cell surface) can protect the virus from
neutralizing antibodies while retaining its antitumor efficacy
after release in the tumor microenvironment (96). OV-tumor
delivery by CAR-T cells could enhance virus delivery to the
tumor and subsequent oncolysis could attract more CAR-T cells,
establishing a positive feedback loop.
REMAINING QUESTIONS AND FUTURE
DIRECTIONS
With such a variety of oncolytic viruses it is hard to know
which one will be best suited for combination with CAR-
T cells. In practical terms, it is difficult to envisage a virus
commercially developed solely for the combination with CAR-
T cells. Therefore, marketed viruses or viruses under clinical
investigation are expected to be the first ones to be used in the
clinic in combination with CAR-T cells.
While the general value of the virus to attract T-cells to
the tumor is widely accepted (53, 97), practical questions on
best delivery routes and dosing schedules are more difficult to
predict. Intratumoral administration of the OV provides larger
amounts of virus in the injected tumors, but it is technically
challenging for visceral tumors or metastases, and non-injected
tumor lesions will be less likely to get any virus to change the
immunosuppressive microenvironment. Systemic intravenous
administration is easier to perform and potentially useful to
reach all metastases, but efficient neutralization of the virus
in the bloodstream, especially with high titers of neutralizing
antibodies raised after the first virus administration, will impose
a barrier for repeated delivery. The immune response to the virus
may also be very different if the virus is injected intratumorally
or systemically. Usually vaccination immunization is performed
subcutaneously or intramuscularly as the immune system does
not respond aggressively to systemic pathogens, partly due to
a lower inflammatory response of liver Kupffer cells compared
to tissue-resident dendritic cells and the tolerogenic nature of
the liver (98). Therefore, the immune response elicited by an
OV replicating in a tumor may be tamed or modulated when
the virus has been detected systemically. Timing of the virus
and CAR-T cells can also impact the outcome. In principle, the
virus should go first to change the immune suppressive tumor
microenviroment, induce a direct lytic effect on tumor cells,
and create a more appropriate environment that attracts the
CAR-T cells. Patient preconditioning should also be considered
prior to therapy. Although the immunostimulatory environment
generated by the virus may bypass the need to lymphodeplete
the patient to promote CAR-T cell expansion, lymphodepletion
could still be a good approach to foster virus replication and
persistence in the tumor while providing an advantage to the
co-administered CAR-T cells (4, 99, 100).
Oncolytic viruses offer a strong inflammatory self-
amplification oncolytic mechanism of action that can also
result in the release of TAA. However, the ability of OV to induce
an anti-tumor immune response is not well-understood. Given
the large number of viral non-self-peptides after treatment with
OV, it is likely that immune responses to the viral epitopes will
dominate the response in a mixture with tumor neoantigens
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(101–103). New strategies to increase the immunogenicity of
tumor epitopes and reduce the immunodominance of viral
antigens are needed to promote epitope spreading (104).
Finally, T cells could also be manipulated to become a better
partner for oncolytic viruses. Virus-specific T cells have been used
as a platform for CAR expression (105). Virus-specific CAR-T
cells retain the ability to recognize both virus-infected and tumor
targets through their native and chimeric receptors, respectively.
Thus, these T-cells could be ideal for a combined treatment with
OV, as the presence of the virus could boost the amplification of
CAR-T cells in the tumor. A drawback of this approach is that a
faster clearance of the OV will occur.
AUTHOR CONTRIBUTIONS
SG and RA conceptualized, wrote, and edited the manuscript.
ACKNOWLEDGMENTS
We thank Anna Wing for extensive revision of this manuscript.
REFERENCES
1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade.
Science (2018) 359:1350–5. doi: 10.1126/science.aar4060
2. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al.
Tisagenlecleucel in children and young adults with B-cell Lymphoblastic
Leukemia. N Engl J Med. (2018) 378:439–48. doi: 10.1056/NEJMoa1709866
3. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook
C, Feldman SA, et al. T cells expressing CD19 chimeric antigen
receptors for acute lymphoblastic leukaemia in children and young
adults: a phase 1 dose-escalation trial. Lancet (2015) 385:517–28.
doi: 10.1016/S0140-6736(14)61403-3
4. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al.
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL
patients. J Clin Invest. (2016) 126:2123–38. doi: 10.1172/JCI85309
5. Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-
term follow-up of CD19 CAR therapy in acute Lymphoblastic Leukemia. N
Eng J Med. (2018) 378:449–59. doi: 10.1056/NEJMoa1709919
6. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al.
Chimeric antigen receptor T cells persist and induce sustained remissions
in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. (2015)
7:303ra139. doi: 10.1126/scitranslmed.aac5415
7. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al.
Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl
J Med. (2017) 377:2545–54. doi: 10.1056/NEJMoa1708566
8. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA,
et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell
lymphoma.N Eng J Med. (2017) 377:2531–44. doi: 10.1056/NEJMoa1707447
9. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al.
Human epidermal growth factor receptor 2 (HER2) -specific chimeric
antigen receptor-modified T cells for the immunotherapy of HER2-positive
sarcoma. J Clin Oncol. (2015) 33:1688–96. doi: 10.1200/JCO.2014.58.0225
10. O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K,
Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-
directed CAR T cells mediates antigen loss and induces adaptive resistance
in patients with recurrent glioblastoma. Sci Transl Med. (2017) 9:eaaa0984.
doi: 10.1126/scitranslmed.aaa0984
11. Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, et al.
Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor
CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res.
(2015) 21:4062–72. doi: 10.1158/1078-0432.CCR-15-0428
12. Beatty GL, O’Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F,
et al. Activity of mesothelin-specific chimeric antigen receptor T cells against
pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology (2018)
155:29–32. doi: 10.1053/j.gastro.2018.03.029
13. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al.
Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N
Engl J Med. (2016) 375:2561–9. doi: 10.1056/NEJMoa1610497
14. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al.
Antitumor activity and long-term fate of chimeric antigen receptor-
positive T cells in patients with neuroblastoma. Blood (2011) 118:6050–6.
doi: 10.1182/blood-2011-05-354449
15. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and
consequences of genetic heterogeneity in cancer evolution. Nature (2013)
501:338–45. doi: 10.1038/nature12625
16. McGranahan N, Swanton C. Biological and therapeutic impact of
intratumor heterogeneity in cancer evolution. Cancer Cell (2015) 27:15–26.
doi: 10.1016/j.ccell.2014.12.001
17. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA.
Case report of a serious adverse event following the administration of T cells
transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther.
(2010) 18:843–51. doi: 10.1038/mt.2010.24
18. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al.
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes
genetically retargeted against carbonic anhydrase IX: first clinical experience.
J Clin Oncol. (2006) 24:e20–e22. doi: 10.1200/JCO.2006.05.9964
19. Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt
DJ, et al. The clinical efficacy of first-generation carcinoembryonic antigen
(CEACAM5)-specific CAR T cells is limited by poor persistence and
transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol
Immunother. (2017) 66:1425–36. doi: 10.1007/s00262-017-2034-7
20. Lim WA, June CH. The principles of engineering immune cells to treat
cancer. Cell (2017) 168:724–40. doi: 10.1016/j.cell.2017.01.016
21. Russell SJ, Barber GN. Oncolytic viruses as antigen-agnostic cancer vaccines.
Cancer Cell (2018) 33:599–605. doi: 10.1016/j.ccell.2018.03.011
22. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N,
Chesney J, et al. Talimogene laherparepvec improves durable response
rate in patients with advanced melanoma. J Clin Oncol. (2015) 33:2780–8.
doi: 10.1200/JCO.2014.58.3377
23. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin
O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration
and improves Anti-PD-1 Immunotherapy. Cell (2017) 170:1109–19 e10.
doi: 10.1016/j.cell.2017.08.027
24. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J,
et al. Randomized, open-label phase II study evaluating the efficacy and
safety of talimogene laherparepvec in combination with ipilimumab versus
ipilimumab alone in patients with advanced, unresectable melanoma. J Clin
Oncol. (2018) 36:1658–67. doi: 10.1200/JCO.2017.73.7379
25. Marelli G, Howells A, Lemoine NR, Wang Y. Oncolytic viral therapy and
the immune system: a double-edged sword against cancer. Front Immunol.
(2018) 9:866. doi: 10.3389/fimmu.2018.00866
26. Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses
in combination cancer immunotherapy. Nat Rev Immunol. (2018) 18(Suppl.
4):1. doi: 10.1038/s41577-018-0014-6
27. Bauzon M, Hermiston T. Armed therapeutic viruses - a disruptive therapy
on the horizon of cancer immunotherapy. Front Immunol. (2014) 5:74.
doi: 10.3389/fimmu.2014.00074
28. Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH. Oncolytic
viruses as engineering platforms for combination immunotherapy. Nat Rev
Cancer (2018) 18:419–32. doi: 10.1038/s41568-018-0009-4
29. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan
GQ, et al. Durable complete responses in heavily pretreated patients with
metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res.
(2011) 17:4550–7. doi: 10.1158/1078-0432.CCR-11-0116
Frontiers in Immunology | www.frontiersin.org 7 October 2018 | Volume 9 | Article 2460
Guedan and Alemany Combining CAR-T and Oncolytic Viruses
30. Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S,
et al. Determinants of response and resistance to CD19 chimeric antigen
receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med.
(2018) 24:563–571. doi: 10.1038/s41591-018-0010-1
31. Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin
J, et al. Regional delivery ofmesothelin-targeted CART cell therapy generates
potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med.
(2014) 6:261ra151. doi: 10.1126/scitranslmed.3010162
32. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, et al.
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of
chimeric antigen receptor-transduced human T cells in solid tumors. Clin
Cancer Res. (2014) 20:4262–73. doi: 10.1158/1078-0432.CCR-13-2627
33. Baitsch L, Fuertes-Marraco SA, Legat A, Meyer C, Speiser DE. The three
main stumbling blocks for anticancer T cells. Trends Immunol. (2012)
33:364–72. doi: 10.1016/j.it.2012.02.006
34. Wherry EJ, KurachiM.Molecular and cellular insights into T cell exhaustion.
Nat Rev Immunol. (2015) 15:486–99. doi: 10.1038/nri3862
35. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor
microenvironment. Science (2015) 348:74–80. doi: 10.1126/science.aaa6204
36. Fry TJ, ShahNN,Orentas RJ, Stetler-StevensonM, YuanCM, Ramakrishna S,
et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or
resistant to CD19-targeted CAR immunotherapy. Nat Med. (2018) 24:20–8.
doi: 10.1038/nm.4441
37. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric
antigen receptor T cells for sustained remissions in leukemia. N Engl J Med.
(2014) 371:1507–17. doi: 10.1056/NEJMoa1407222
38. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al.
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N
Engl J Med. (2013) 368:1509–18. doi: 10.1056/NEJMoa1215134
39. Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, et al.
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.
Mol Ther. (2014) 22:623–33. doi: 10.1038/mt.2013.262
40. Wing A, Fajardo CA, Posey AD Jr, Shaw C, Da T, Young RM, et al.
Improving CART-cell therapy of solid tumors with oncolytic virus-driven
production of a bispecific T-cell engager. Cancer Immunol Res. (2018) 6:605–
16. doi: 10.1158/2326-6066.CIR-17-0314
41. Song DG, Ye Q, Poussin M, Chacon JA, Figini M, Powell DJ, et al. Effective
adoptive immunotherapy of triple-negative breast cancer by folate receptor-
alpha redirected CART cells is influenced by surface antigen expression level.
J Hematol Oncol. (2016) 9:56. doi: 10.1186/s13045-016-0285-y
42. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y,
et al. Combinational targeting offsets antigen escape and enhances effector
functions of adoptively transferred T cells in glioblastoma.Mol Ther. (2013)
21:2087–101. doi: 10.1038/mt.2013.185
43. Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA,
et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate
tumor antigen escape. J Clin Invest. (2016) 126:3036–52. doi: 10.1172/JCI
83416
44. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al.
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells
induce anti-tumor activity in solid malignancies. Cancer Immunol Res.
(2014) 2:112–20. doi: 10.1158/2326-6066.CIR-13-0170
45. Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ,
Flores CT, et al. EGFRvIII mCAR-modified T-cell therapy cures mice
with established intracerebral glioma and generates host immunity
against tumor-antigen loss. Clin Cancer Res. (2014) 20:972–84.
doi: 10.1158/1078-0432.CCR-13-0709
46. Russell L, Peng KW. The emerging role of oncolytic virus therapy against
cancer. Chin Clin Oncol. (2018) 7:16. doi: 10.21037/cco.2018.04.04
47. Geletneky K, Hajda J, Angelova AL, Leuchs B, Capper D, Bartsch AJ,
et al. Oncolytic H-1 parvovirus shows safety and signs of immunogenic
activity in a first phase I/IIa glioblastoma trial.Mol Ther. (2017) 25:2620–34.
doi: 10.1016/j.ymthe.2017.08.016
48. Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R,
Weinberg JS, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic
adenovirus, replication and immunotherapeutic effects in recurrent
malignant glioma. J Clin Oncol. (2018) 36:1419–27. doi: 10.1200/JCO.2017.7
5.8219
49. Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, et al.
Remission of disseminated cancer after systemic oncolytic virotherapy.Mayo
Clin Proc. (2014) 89:926–33. doi: 10.1016/j.mayocp.2014.04.003
50. Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC,
et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine
for recurrent high-grade glioma. Sci Transl Med. (2016) 8:341ra75.
doi: 10.1126/scitranslmed.aad9784
51. Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP,
Friedman AH, et al. Recurrent glioblastoma treated with recombinant
poliovirus. N Eng J Med. (2018) 379:150–61. doi: 10.1056/NEJMoa1716435
52. McDermott D, Lebbé C, Hodi FS, Maio M, Weber JS, Wolchok JD,
et al. Durable benefit and the potential for long-term survival with
immunotherapy in advanced melanoma. Cancer Treat Rev. (2014) 40:1056–
64. doi: 10.1016/j.ctrv.2014.06.012
53. Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L,
Bozada JM, et al. Phase 1 study of intravenous administration of the chimeric
adenovirus enadenotucirev in patients undergoing primary tumor resection.
J ImmunoTherapy Cancer (2017) 5:71. doi: 10.1186/s40425-017-0277-7
54. Woller N, Gurlevik E, Fleischmann-Mundt B, Schumacher A, Knocke S,
Kloos AM, et al. Viral infection of tumors overcomes resistance to PD-1-
immunotherapy by broadening neoantigenome-directed T-cell responses.
Mol Ther. (2015) 23:1630–40. doi: 10.1038/mt.2015.115
55. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P,
et al. Localized oncolytic virotherapy overcomes systemic tumor resistance
to immune checkpoint blockade immunotherapy. Sci Transl Med. (2014)
6:226ra32. doi: 10.1126/scitranslmed.3008095
56. Rojas JJ, Sampath P, Hou W, Thorne SH. Defining effective combinations
of immune checkpoint blockade and oncolytic virotherapy. Clin Cancer Res.
(2015) 21:5543–51. doi: 10.1158/1078-0432.CCR-14-2009
57. Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, et al.
Intravenous delivery of oncolytic reovirus to brain tumor patients
immunologically primes for subsequent checkpoint blockade. Sci Transl
Med. (2018) 10:eaam7577. doi: 10.1126/scitranslmed.aam7577
58. Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT,
Varette O, et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes
triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med.
(2018) 10:eaao1641. doi: 10.1126/scitranslmed.aao1641
59. Mogensen TH. Pathogen recognition and inflammatory signaling in innate
immune defenses. Clin Microbiol Rev. (2009) 22:240–73, Table of Contents.
doi: 10.1128/CMR.00046-08
60. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P,
et al. Consensus guidelines for the detection of immunogenic cell death.
Oncoimmunology (2014) 3:e955691. doi: 10.4161/21624011.2014.955691
61. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way
is a key to eliciting potent antitumor immunity. Front Oncol. (2014) 4:74.
doi: 10.3389/fonc.2014.00074
62. Garcia-Sastre A, Biron CA. Type 1 interferons and the virus-
host relationship: a lesson in detente. Science (2006) 312:879–82.
doi: 10.1126/science.1125676
63. Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action
for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin
Cancer Res. (2016) 22:1048–54. doi: 10.1158/1078-0432.CCR-15-2667
64. Benencia F, Courreges MC, Conejo-Garcia JR, Mohamed-Hadley A, Zhang
L, Buckanovich RJ, et al. HSV oncolytic therapy upregulates interferon-
inducible chemokines and recruits immune effector cells in ovarian cancer.
Mol Ther. (2005) 12:789–802. doi: 10.1016/j.ymthe.2005.03.026
65. Steele L, Errington F, Prestwich R, Ilett E, Harrington K, Pandha
H, et al. Pro-inflammatory cytokine/chemokine production by reovirus
treated melanoma cells is PKR/NF-kappaB mediated and supports innate
and adaptive anti-tumour immune priming. Mol Cancer (2011) 10:20.
doi: 10.1186/1476-4598-10-20
66. Russell SJ, Peng KW. Oncolytic virotherapy: a contest between apples and
oranges.Mol Ther. (2017) 25:1107–16. doi: 10.1016/j.ymthe.2017.03.026
67. Ajina A, Maher J. Prospects for combined use of oncolytic
viruses and CAR T-cells. J ImmunoTherapy Cancer (2017) 5:90.
doi: 10.1186/s40425-017-0294-6
68. Guedan S, Grases D, Rojas JJ, Gros A, Vilardell F, Vile R, et al. GALV
expression enhances the therapeutic efficacy of an oncolytic adenovirus by
Frontiers in Immunology | www.frontiersin.org 8 October 2018 | Volume 9 | Article 2460
Guedan and Alemany Combining CAR-T and Oncolytic Viruses
inducing cell fusion and enhancing virus distribution. Gene Ther. (2012)
19:1048–57. doi: 10.1038/gt.2011.184
69. Carew JF, Kooby DA, Halterman MW, Kim SH, Federoff HJ, Fong Y.
A novel approach to cancer therapy using an oncolytic herpes virus to
package amplicons containing cytokine genes. Mol Ther. (2001) 4:250–6.
doi: 10.1006/mthe.2001.0448
70. Stephenson KB, Barra NG, Davies E, Ashkar AA, Lichty BD. Expressing
human interleukin-15 from oncolytic vesicular stomatitis virus improves
survival in a murine metastatic colon adenocarcinoma model through the
enhancement of anti-tumor immunity. Cancer Gene Ther. (2012) 19:238–46.
doi: 10.1038/cgt.2011.81
71. Wang P, Li X, Wang J, Gao D, Li Y, Li H, et al. Re-designing Interleukin-12 to
enhance its safety and potential as an anti-tumor immunotherapeutic agent.
Nat Commun. (2017) 8:1395. doi: 10.1038/s41467-017-01385-8
72. Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, et al.
Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine
expressing RANTES elicits potent antitumor immunity. J Immunother.
(2009) 32:145–56. doi: 10.1097/CJI.0b013e318193d31e
73. Li J, O’Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, et al. Chemokine
expression from oncolytic vaccinia virus enhances vaccine therapies of
cancer.Mol Ther. (2011) 19:650–7. doi: 10.1038/mt.2010.312
74. Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P,
et al. Intratumoral modulation of the inducible co-stimulator ICOS by
recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat
Commun. (2017) 8:14340. doi: 10.1038/ncomms14340
75. Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion
enhances the therapeutic activity of an oncolytic vaccinia
virus expressing 4-1BB ligand. Cancer Res. (2009) 69:8516–25.
doi: 10.1158/0008-5472.CAN-09-2522
76. Andarini S, Kikuchi T, Nukiwa M, Pradono P, Suzuki T, Ohkouchi S, et al.
Adenovirus vector-mediatedin vivogene transfer of OX40 ligand to tumor
cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res.
(2004) 64:3281–7. doi: 10.1158/0008-5472.CAN-03-3911
77. Ullenhag G, Loskog AS. AdCD40L–crossing the valley of death? Int Rev
Immunol. (2012) 31:289–98. doi: 10.3109/08830185.2012.692844
78. Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de
Sostoa J, et al. Oncolytic adenoviral delivery of an EGFR-targeting T-
cell engager improves antitumor efficacy. Cancer Res. (2017) 77:2052–63.
doi: 10.1158/0008-5472.CAN-16-1708
79. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-
armed oncolytic vaccinia virus significantly enhances antitumor therapy.Mol
Ther. (2014) 22:102–11. doi: 10.1038/mt.2013.240
80. Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, et al.
Targeted cancer immunotherapy with oncolytic adenovirus coding for a
fully human monoclonal antibody specific for CTLA-4. Gene Ther. (2012)
19:988–98. doi: 10.1038/gt.2011.176
81. Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, et al.
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus
therapy.Mol Ther. (2014) 22:1949–59. doi: 10.1038/mt.2014.160
82. Bartee MY, Dunlap KM, Bartee E. Tumor-localized secretion of soluble
PD1 enhances oncolytic virotherapy. Cancer Res. (2017) 77:2952–63.
doi: 10.1158/0008-5472.CAN-16-1638
83. Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, et al.
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a
scFv against programmed cell death−1 (PD-1) allows their intratumoral
delivery and an improved tumor-growth inhibition.Oncoimmunology (2016)
5:e1220467. doi: 10.1080/2162402X.2016.1220467
84. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R.
Hyaluronidase expression by an oncolytic adenovirus enhances its
intratumoral spread and suppresses tumor growth. Mol Ther. (2010)
18:1275–83. doi: 10.1038/mt.2010.79
85. Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M,
Robinson M, et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus
prolongs survival of tumor-bearing mice. Cancer Res. (2007) 67:4399–407.
doi: 10.1158/0008-5472.CAN-06-4260
86. Morgan RA. Human tumor xenografts, the good, the bad, and the ugly.Mol
Ther. (2012) 20:882–4. doi: 10.1038/mt.2012.73
87. Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, et al.
Armed oncolytic virus enhances immune functions of chimeric antigen
receptor-modified T cells in solid tumors. Cancer Res. (2014) 74:5195–205.
doi: 10.1158/0008-5472.CAN-14-0697
88. Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, et al.
Pancreatic cancer therapy with combined mesothelin-redirected
chimeric antigen receptor T cells and cytokine-armed oncolytic
adenoviruses. JCI Insight (2018) 3:99573. doi: 10.1172/jci.insight.
99573
89. Moon EK, Wang LS, Bekdache K, Lynn RC, Lo A, Thorne SH, et al.
Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified
T cells, enhances the efficacy of adoptive T cell therapy and vaccines.
Oncoimmunology (2018) 7:e1395997. doi: 10.1080/2162402X.2017.13
95997
90. Tanoue K, Rosewell Shaw A, Watanabe N, Porter C, Rana B, Gottschalk S,
et al. Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances
antitumor effects of chimeric antigen receptor T cells in solid tumors. Cancer
Res. (2017) 77:2040–51. doi: 10.1158/0008-5472.CAN-16-1577
91. Rosewell Shaw A, Porter CE, Watanabe N, Tanoue K, Sikora A,
Gottschalk S, et al. Adenovirotherapy delivering cytokine and checkpoint
inhibitor augments CAR T cells against metastatic head and neck
cancer. Mol Therapy (2017) 25:2440–51. doi: 10.1016/j.ymthe.2017.
09.010
92. VanSeggelen H, Tantalo DG, Afsahi A, Hammill JA, Bramson JL. Chimeric
antigen receptor-engineered T cells as oncolytic virus carriers. Mol Ther
Oncolytics (2015) 2:15014. doi: 10.1038/mto.2015.14
93. Agrahari V, Agrahari V, Mitra AK. Next generation drug delivery,
circulatory cells-mediated nanotherapeutic approaches. Exp Opin
Drug Deliv. (2016) 14:285–9. doi: 10.1080/17425247.2017.12
54614
94. Yotnda P. Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood
(2004) 104:2272–80. doi: 10.1182/blood-2003-11-3803
95. Jennings VA, Ilett EJ, Scott KJ, West EJ, Vile R, Pandha H, et al.
Lymphokine-activated killer and dendritic cell carriage enhances
oncolytic reovirus therapy for ovarian cancer by overcoming antibody
neutralization in ascites. Int J Cancer (2014) 134:1091–101. doi: 10.1002/ijc.
28450
96. Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L, et al. Tumor-
targeted, systemic delivery of therapeutic viral vectors using hitchhiking on
antigen-specific T cells. Nat Med. (2005) 11:1073–81. doi: 10.1038/nm1297
97. Heinzerling L, Kunzi V, Oberholzer PA, Kundig T, Naim H, Dummer
R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts
antitumor immune responses in vivo and targets interferon-resistant
tumor cells. Blood (2005) 106:2287–94. doi: 10.1182/blood-2004-1
1-4558
98. Robinson MW, Harmon C, O’Farrelly C. Liver immunology and its role
in inflammation and homeostasis. Cell Mol Immunol. (2016) 13:267–76.
doi: 10.1038/cmi.2016.3
99. Peng KW, Myers R, Greenslade A, Mader E, Greiner S, Federspiel MJ,
et al. Using clinically approved cyclophosphamide regimens to control the
humoral immune response to oncolytic viruses. Gene Ther. (2013) 20:255–
61. doi: 10.1038/gt.2012.31
100. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ,
et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances
the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp
Med. (2005) 202:907–12. doi: 10.1084/jem.20050732
101. Akram A, Inman RD. Immunodominance: A pivotal principle in
host response to viral infections. Clin Immunol. (2012) 143:99–115.
doi: 10.1016/j.clim.2012.01.015
102. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin
JG, et al. Human adenovirus-specific T cells modulate HIV-specific T cell
responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest. (2012) 122:359–
67. doi: 10.1172/JCI60202
103. Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P,
Thompson J, et al. Interference of CD40L-mediated tumor immunotherapy
by oncolytic vesicular stomatitis virus. Hum Gene Ther. (2010) 21:439–50.
doi: 10.1089/hum.2009.143
Frontiers in Immunology | www.frontiersin.org 9 October 2018 | Volume 9 | Article 2460
Guedan and Alemany Combining CAR-T and Oncolytic Viruses
104. Rodriguez-Garcia A, Svensson E, Gil-Hoyos R, Fajardo CA, Rojas LA,
Arias-Badia M, et al. Insertion of exogenous epitopes in the E3-
19K of oncolytic adenoviruses to enhance TAP-independent presentation
and immunogenicity. Gene Ther. (2015) 22:596–601. doi: 10.1038/gt.
2015.41
105. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti
G, et al. Virus-specific T cells engineered to coexpress tumor-
specific receptors: persistence and antitumor activity in individuals
with neuroblastoma. Nat Med. (2008) 14:1264–70. doi: 10.1038/
nm.1882
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Guedan and Alemany. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 10 October 2018 | Volume 9 | Article 2460
